|
|
ViroPharma Incorporated - Comparative Business Analysis Snapshot
Business Description
ViroPharma Incorporated. The Group's principal activity is to develop and commercialize products that address serious diseases treated by physician specialists, in areas including hospital settings, transplant medicine and gastroenterology. It is focused on the marketing and sale of its commercialized product, Vancocin, an oral capsule to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The development activities are currently focused on product candidates to treat viral diseases including those caused by cytomegalovirus (CMV) and hepatitis C (HCV) infections. As on 21-Oct-2008, it acquired Lev Pharmaceuticals Inc.
Competitor Analysis
This analysis compares ViroPharma Incorporated with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
